<DOC>
	<DOC>NCT00785408</DOC>
	<brief_summary>A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.</brief_summary>
	<brief_title>Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<criteria>Is obese with a body mass index (BMI) ≥30 kg/m^2 to ≤45 kg/m^2, or is overweight with a BMI ≥27 kg/m^2 to &lt;30 kg/m^2 and has at least one weightrelated comorbidity (dyslipidemia, impaired fasting glucose, hypertension, obstructive sleep apnea syndrome, polycystic ovary syndrome, and/or osteoarthritis) Has had a major change in daily physical activity (e.g., initiation of an exercise program) or has been enrolled in a weight loss program within 2 months prior to study start Has received AC2307 or pramlintide in a clinical study or has received prior treatment with pramlintide (SYMLIN®) or calcitonin Has received any investigational drug within 1 month or within a period corresponding to five times the halflife of the investigational drug, whichever is greater, before study start Has donated blood within 2 months before study start or is planning to donate blood during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>obesity</keyword>
	<keyword>overweight</keyword>
	<keyword>weight loss</keyword>
	<keyword>Amylin</keyword>
	<keyword>AC2307</keyword>
</DOC>